Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C generates $20mm so far for Sutro Biopharma; adds $16.5mm

Executive Summary

Protein therapeutics developer Sutro Biopharma Inc. (formerly Fundamental Applied Biology) has raised $20mm in its two-tranche Series C financing round led by new investor Skyline Ventures. Other first-time backers Lilly Ventures and Amgen Ventures were joined by returning shareholders SV Life Sciences and Alta Partners. In total, Sutro plans to raise $36.5mm in the round, with the remaining funds to come after milestones are met (before the end of 2012). The company will apply the funds to the ongoing development of "biobetters" with improved properties over existing drugs using its biochemical synthesis technology. Two representatives from Lilly Ventures will join Sutro's board.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies